Skip directly to content

HCP & HCO annual Disclosure reports

Working with healthcare professionals (HCPs) and healthcare organisations (HCOs) helps us to deliver better care for patients, and for the doctors who care for them.
 

By engaging in two-way conversations, we can use our knowledge to help doctors get the most out of our medicines and learn how we can change things to benefit their patients.

We believe HCPs should be paid for the time they invest and expertise they offer us in this important work, but it is right that we continually review how this works in practice. We hope that the healthcare professionals we work with feel the same, which is why we will only work with those who are happy to share information about our work together in the public domain.

We think it's important the public feels confident our relationships are appropriate and beneficial. That is why we are committed to transparency.

 

2016 Payment Report

A snapshop of the payments made towards UK Research & Development, Healthcare Professionals and Healthcare Organisations in 2016:

 

 

Research & Development
such as clinical trials, clinical & research collaboration and research grants
£32,158,963
(75.1%)
HCP contribution to cost of events
such as registration fees, travel and accommodation
£687,585
(1.6%)
HCP fees for service and related expenses
such as speaker engagements, general consulting, travel and accommodation
£2,597,467
(6.0%)
HCO contribution to cost of events
such as sponsorship agreements, registration fees, travel and accommodation
£1,640,822
(3.8%)
HCO donations and grants
such as charitable contributions, education grants and studentships
£3,852,334
(8.9%)
HCO Joint Working £219,353
(0.5%)
HCO fees for service and related expenses
such as charitable contributions, education grants and studentships
£1,663,250
(3.8%)
  Total £42,819,775

 

Download Pfizer’s 2016 payments to UK Healthcare Professionals and Healthcare Organisations report. If you would like to find out more about how we put the data together, you can view our Methological Note.

[Data gathered 30 August 2017]

 

Historical Payment Reports

2015 Report

A snapshop of the payments made towards UK Research & Development, Healthcare Professionals and Healthcare Organisations in 2015:

 

 

Research & Development
such as clinical trials, clinical & research collaboration and research grants
£20,632,508
(71.7%)
HCP contribution to cost of events
such as registration fees, travel and accommodation
£600,886
(2.1%)
HCP fees for service and related expenses
such as speaker engagements, general consulting, travel and accommodation
£1,908,099
(6.6%)
HCO contribution to cost of events
such as sponsorship agreements, registration fees, travel and accommodation
£1,857,985
(6.5%)
HCO donations and grants
such as charitable contributions, education grants and studentships
£2,463,710
(8.6%)
HCO Joint Working £46,089
(0.2%)
HCO fees for service and related expenses
such as charitable contributions, education grants and studentships
£1,283,744
(4.5%)
  Total £28,793,021

 

Download Pfizer’s 2015 payments to UK Healthcare Professionals and Healthcare Organisations report.

[Data gathered 30 August 2017]

2014 Report
Fees for Service/consultancy Number of HCPs* Total amount paid
Speaking/chairing at a speaker meeting 955 £1,208,706
Chairing.participating in an advisory board 302 £519,715
Other consultancy 144 £285,163
Total** 1,260 £2,013,584
Sponsorship to attend third party medical education meetings  
Number of HCPs supported*** 574
Number of meeting attendances 609
Total amount paid £234,090

* Some individual HCPs will have been engaged multiple times for each consultancy activity e.g. speaking at a several speaker meetings during the year. These HCPs will only be counted once in each type of activity.

** Some individual HCPs will have been engaged for multiple types of consultancy activities e.g. speaking at a speaker meeting and chairing an advisory board. These HCPs will only be counted once in this total.

***Some HCPs received sponsorship to attend more than one meeting.

2013 Report
Fees for Service/consultancy Number of HCPs* Total amount paid
Speaking/chairing at a speaker meeting 1,349 £1,414,691
Chairing.participating in an advisory board 272 £284,378
Other consultancy 44 £70,789
Total** 1,553 £1,769,858
Sponsorship to attend third party medical education meetings  
Number of HCPs supported*** 786
Number of meeting attendances 848
Total amount paid £365,160

* Some individual HCPs will have been engaged multiple times for each consultancy activity e.g. speaking at a several speaker meetings during the year. These HCPs will only be counted once in each type of activity.

** Some individual HCPs will have been engaged for multiple types of consultancy activities e.g. speaking at a speaker meeting and chairing an advisory board. These HCPs will only be counted once in this total.

***Some HCPs received sponsorship to attend more than one meeting.

2012 Report
Fees for Service/consultancy Number of HCPs* Total amount paid
Speaking/chairing at a speaker meeting 1,939 £1,930,661
Chairing.participating in an advisory board 142 £127,359
Other consultancy 311 £968,943
Total** 2,023 £3,026,964
Sponsorship to attend third party medical education meetings  
Number of HCPs supported*** 2,689
Number of meeting attendances 3,486
Total amount paid £1,377,112

* Some individual HCPs will have been engaged multiple times for each consultancy activity e.g. speaking at a several speaker meetings during the year. These HCPs will only be counted once in each type of activity.

** Some individual HCPs will have been engaged for multiple types of consultancy activities e.g. speaking at a speaker meeting and chairing an advisory board. These HCPs will only be counted once in this total.

***Some HCPs received sponsorship to attend more than one meeting.

Key Terms
"Fees for service/consultancy"

Refers to activities where healthcare professionals provide us with a service that we pay them for – such as speaking at meetings, chairing meetings, participating in advisory boards and providing other consultancy time. An example of other consultancy would be when Pfizer works with a healthcare professional as a consultant to advise on an issue such as drug development, the role of a medicine in a patient pathway, health economics or best clinical practice.

Collaborations between healthcare professionals and the pharmaceutical industry are essential to gaining the real-world information necessary to develop and deliver innovative treatment choices that improve the health and wellbeing of patients, and to support research and development. These relationships also help the flow of information between industry and the NHS. As an integral part of the medicines development process it is appropriate that healthcare professionals are fairly compensated for their time and expertise.

 

"Sponsorship to attend third party medical education meetings"

Refers to the support we provide to healthcare professionals to attend independent third party medical education meetings: contributions towards registration fees, international travel and accommodation costs. From the 15th March 2012 to the 30th November 2014, Pfizer’s approach to the sponsorship of these types of meetings was to provide an overall contribution to a healthcare professional to support their attendance based on the location of the meeting.

This type of funding approach is consistent across our organisation in the UK and with all the HCPs we support. We are open and transparent as to how that funding is provided. The table below shows the maximum levels of funding provided up to the 30th November 2014:

Meetings within the UK Up to £250
Meetings within Europe Up to £700
Meetings outside Europe Up to £1,000

This approach to funding was updated as of the 1st  December 2014 and Pfizer is now only supporting registration fees to 3rd party medical education meetings up to an amount of £750 irrespective of whether the meeting is in the UK, Europe or outside Europe. From 2016, no partial contributions will be made unless specifically requested by an HCP, for example, when they have already secured partial sponsorship elsewhere.